|Awarded On||August 18, 2021|
|Title||Antibody-like therapeutics that target polyclonal T cells to CMV-positive glioblastomas|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Jennifer Maynard|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Glioblastoma is a devastating brain tumor with no long-term cure. Current therapies rely on surgical resection, high-dose radiation and temozolomide chemotherapy, which significantly decrease patient quality of life and only provide a brief respite from disease. Immunotherapies could present a solution: antibodies and engineered T cells have demonstrated impressive clinical successes for some cancers, but a key challenge in GBM is identification of surface antigens that allow targeting of tumor but not healthy tissues. Notably, cytomegalovirus (CMV) proteins have been observed in >90% of glioblastomas but not healthy adjacent brain tissues, providing a possible means to target novel thera...